Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Appointed director
CC transcript
|
|
X4 Pharmaceuticals, Inc (XFOR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/22/2021 |
GN
| X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021 |
| 04/07/2021 |
GN
| X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference |
| 03/19/2021 |
GN
| X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement Financing |
| 03/04/2021 |
GN
| X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update |
| 01/19/2021 |
GN
| X4 Pharmaceuticals to Participate at the Virtual B. Riley Oncology Institutional Investor Conference |
| 01/07/2021 |
GN
| X4 Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect Conference |
| 12/14/2020 |
GN
| X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer |
| 12/01/2020 |
GN
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 11/10/2020 |
GN
| X4 Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference |
| 11/05/2020 |
GN
| X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update |
| 11/02/2020 |
GN
| X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific Officer |
| 10/08/2020 |
GN
| X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome |
| 10/01/2020 |
GN
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 10/01/2020 |
GN
| X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton |
| 09/03/2020 |
GN
| X4 Pharmaceuticals to Participate in Three September Virtual Investor Conferences |
| 09/02/2020 |
GN
| X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in ‘Blood' - the Official Journal of the American Society of Hematology |
| 09/01/2020 |
GN
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08/10/2020 |
GN
| X4 Pharmaceuticals to Present and Participate in the Canaccord Genuity's 40th Annual Growth Conference |
| 08/05/2020 |
GN
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07/16/2020 |
GN
| X4 Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on July 30, 2020 |
| 07/01/2020 |
GN
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06/12/2020 |
GN
| X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020 |
| 06/11/2020 |
GN
| X4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer |
| 06/01/2020 |
GN
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 02/14/2019 |
GN
| Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis — Fundamental Analysis, Key Performance Indications |
| 11/27/2018 |
GN
| Arsanis and X4 Pharmaceuticals Agree to Merger |
| 11/09/2018 |
GN
| Arsanis Reports Financial Results for Third Quarter 2018 |
| 08/20/2018 |
GN
| New Research: Key Drivers of Growth for Harmonic, Astec Industries, Marlin Business Services, Arsanis, SunOpta, and Rhythm Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production |
| 06/28/2018 |
GN
| Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100 |
| 04/09/2018 |
GN
| Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement |
| 11/15/2017 |
GN
| Arsanis Announces Pricing of Initial Public Offering |
|
|